Clinical Trial

Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis. Through this prospective, single-center, open-label clinical trial, we aim to investigate the effectiveness and safety of Telitacicept in refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis by add-on therapy of Telitacicept combined with traditional treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-15.
Trial Details
NCT Number NCT06510283
Lead Sponsor Beijing Tongren Hospital
Conditions Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Enrollment 10 participants
Start Date 2024-12-01
Primary Completion 2027-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-20